{"id":"W2740393355","doi":"10.1093/annonc/mdx339","title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":258,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; F. Hoffmann-La Roche; Roche","keywords":"Vemurafenib; Dacarbazine; Medicine; Confidence interval; Hazard ratio; Internal medicine; Metastatic melanoma; Progression-free survival; Melanoma; Gastroenterology; Oncology; Chemotherapy; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001280435,0.0009519703,0.00169728,0.0002026967,0.0002320003,0.00092976,0.0005298927,0.0007006317,0.001783828],"category_scores_gemma":[0.0009903872,0.000412796,0.002095418,0.0002326023,0.0004569187,0.0007880582,0.0003911702,0.001959415,0.0003488002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007712723,"about_ca_system_score_gemma":0.0005833199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008431884,"about_ca_topic_score_gemma":0.002371775,"domain_scores_codex":[0.9995809,0.0002138041,0.00002053037,0.00005671828,0.00004021648,0.00008779708],"domain_scores_gemma":[0.9996634,0.00008114579,0.00009732751,0.00003406669,0.00002062941,0.0001034616],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8918924,0.003499961,0.009892793,0.001141225,0.005480258,0.0001506114,0.0001039049,0.003003365,0.009927466,0.0003547744,0.003273144,0.07128015],"study_design_scores_gemma":[0.8263823,0.0866906,0.06815103,0.0001443879,0.007291242,0.0003184315,0.0001553063,0.003055059,0.002354978,0.001051258,0.004313373,0.00009215372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906645,0.006595629,0.0002945755,0.0005552655,0.0001775321,0.000138329,0.0004468793,0.00004683572,0.001080567],"genre_scores_gemma":[0.9955441,0.001866854,0.0002753481,0.0004369141,0.0001317754,0.0001781053,0.0006354518,0.00001640662,0.0009150112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001783828,"threshold_uncertainty_score":0.006771684,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04370504422132651,"score_gpt":0.3263825167606763,"score_spread":0.2826774725393497,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}